Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil

Detalhes bibliográficos
Autor(a) principal: Justino, Maria Cleonice Aguiar
Data de Publicação: 2011
Outros Autores: Linhares, Alexandre da Costa, Lanzieri, Tatiana. M, Miranda, Ylle, Mascarenhas, Joana D'Arc Pereira, Abreu, Erika, Guerra, Sylvia de Fátima dos Santos, Oliveira, Alessilva S. L, Silva, Veronice B. da, Sanchez, Nervo, Meyer, Nadia, Shafi, Fakrudeen, Ortega-Barria, Eduardo, Soriano-Gabarró, Montse, Colindres, Romulo E
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Digital do Instituto Evandro Chagas (Patuá)
Texto Completo: https://patua.iec.gov.br/handle/iec/946
Resumo: Background: Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. Methods: Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (±8 and ±6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio X 100%). Results: Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1–86.0) using neighborhood controls and 40.0% (95% CI: 14.2–58.1) using hospital controls. VE in children 3 to 11 months and ≥12 months of age was 95.7% (95% CI: 67.8–99.4) and 65.1% (95% CI: 37.2–80.6) using neighborhood controls, and 55.6% (95% CI: 12.3–77.5) and 32.1% (95% CI: 3.7–55.5) using hospital controls. G2P[4] accounted for 82.0% of RVGE hospitalizations. G2P[4]-specific VE was 75.4% (95% CI: 56.7–86.0) using neighborhood controls and 38.9% (95% CI: 11.1– 58.0) using hospital controls. Conclusions: Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 month months. However, protection in children ≥12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls.
id IEC-2_67b68cdada1abff8657d738841ab3c7e
oai_identifier_str oai:patua.iec.gov.br:iec/946
network_acronym_str IEC-2
network_name_str Repositório Digital do Instituto Evandro Chagas (Patuá)
repository_id_str
spelling Justino, Maria Cleonice AguiarLinhares, Alexandre da CostaLanzieri, Tatiana. MMiranda, YlleMascarenhas, Joana D'Arc PereiraAbreu, ErikaGuerra, Sylvia de Fátima dos SantosOliveira, Alessilva S. LSilva, Veronice B. daSanchez, NervoMeyer, NadiaShafi, FakrudeenOrtega-Barria, EduardoSoriano-Gabarró, MontseColindres, Romulo E2016-01-26T11:39:50Z2016-01-26T11:39:50Z2011JUSTINO, Maria Cleonice Aguiar et al. Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil. The Pediatric Infectious Disease Journal, v. 30, n. 5, p. 396-401, May 2011. DOI: https://doi.org/10.1097/INF.0b013e3182055cc2.1871-0336https://patua.iec.gov.br/handle/iec/94610.1097/INF.0b013e3182055cc2Background: Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. Methods: Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (±8 and ±6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio X 100%). Results: Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1–86.0) using neighborhood controls and 40.0% (95% CI: 14.2–58.1) using hospital controls. VE in children 3 to 11 months and ≥12 months of age was 95.7% (95% CI: 67.8–99.4) and 65.1% (95% CI: 37.2–80.6) using neighborhood controls, and 55.6% (95% CI: 12.3–77.5) and 32.1% (95% CI: 3.7–55.5) using hospital controls. G2P[4] accounted for 82.0% of RVGE hospitalizations. G2P[4]-specific VE was 75.4% (95% CI: 56.7–86.0) using neighborhood controls and 38.9% (95% CI: 11.1– 58.0) using hospital controls. Conclusions: Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 month months. However, protection in children ≥12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.GlaxoSmithKline. Rio de Janeiro, RJ, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas, Belém, PA, Brasil.GlaxoSmithKline. Rio de Janeiro, RJ, Brasil.GlaxoSmithKline Biologicals. Wavre, Belgium.GlaxoSmithKline Biologicals. Bangalore, India.GlaxoSmithKline. Rio de Janeiro, RJ, Brasil.GlaxoSmithKline Biologicals, Wavre, Belgium.GlaxoSmithKline. Rio de Janeiro, RJ, Brasilapplication/pdfengLippincott, Williams & WilkinsEffectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article20082009Gastroenterite / virologiaRotavirus / isolamento & purificaçãoVacinas contra RotavirusHospitalizaçãoinfo:eu-repo/semantics/embargoedAccessreponame:Repositório Digital do Instituto Evandro Chagas (Patuá)instname:Instituto Evandro Chagas (IEC)instacron:IECTEXTfile_1.pdf.txtfile_1.pdf.txtExtracted texttext/plain39133https://patua.iec.gov.br/bitstreams/f67cca24-1d20-462c-9751-5f7b70e1e4cb/downloadb4a728b35026c7be44f04c20fd8e113bMD52Effectiveness of the monovalent G1P[8] Human Rotavirus vaccine against Hospitalization for severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil .pdf.txtEffectiveness of the monovalent G1P[8] Human Rotavirus vaccine against Hospitalization for severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil .pdf.txtExtracted texttext/plain39133https://patua.iec.gov.br/bitstreams/0dcb8f4b-7333-47a4-9ca1-2e75bd1902b7/downloadb4a728b35026c7be44f04c20fd8e113bMD53Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.pdf.txtEffectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.pdf.txtExtracted texttext/plain39133https://patua.iec.gov.br/bitstreams/98ac4a4d-20c7-4832-9498-6325a362efa9/downloadb4a728b35026c7be44f04c20fd8e113bMD55Acesso Embargado.pdf.txtAcesso Embargado.pdf.txtExtracted texttext/plain2https://patua.iec.gov.br/bitstreams/b3b14f19-ba3c-41f1-a0a8-ef28fd417ccd/downloade1c06d85ae7b8b032bef47e42e4c08f9MD511THUMBNAILEffectiveness of the monovalent G1P[8] Human Rotavirus vaccine against Hospitalization for severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil .pdf.jpgEffectiveness of the monovalent G1P[8] Human Rotavirus vaccine against Hospitalization for severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil .pdf.jpgIM Thumbnailimage/jpeg5333https://patua.iec.gov.br/bitstreams/f72dc534-f82d-4f1b-a92b-a4e67d107297/download45ce6e12ef4e729cfe9475020205fe2fMD54Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.pdf.jpgEffectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.pdf.jpgGenerated Thumbnailimage/jpeg1763https://patua.iec.gov.br/bitstreams/3a566108-0153-4295-b811-97d15d644748/download5b11fe0a61e28487f10cb9b29605b388MD56Acesso Embargado.pdf.jpgAcesso Embargado.pdf.jpgGenerated Thumbnailimage/jpeg3095https://patua.iec.gov.br/bitstreams/cd7006d8-5f36-4a95-9515-b88351b638a6/download71859d578212107f7f8c49a4ce09d9eeMD512ORIGINALAcesso Embargado.pdfAcesso Embargado.pdfapplication/pdf551083https://patua.iec.gov.br/bitstreams/bd078aab-ce17-4f7a-ae40-a3acc2ccbe79/downloadc9a9c128e29cac82a5d7fdf3f4e6da73MD57LICENSElicense.txtlicense.txttext/plain; charset=utf-82182https://patua.iec.gov.br/bitstreams/13470106-fb99-4821-acab-52cc99ecc50a/download11832eea31b16df8613079d742d61793MD510iec/9462022-10-20 21:34:04.505oai:patua.iec.gov.br:iec/946https://patua.iec.gov.brRepositório InstitucionalPUBhttps://patua.iec.gov.br/oai/requestclariceneta@iec.gov.br || Biblioteca@iec.gov.bropendoar:2022-10-20T21:34:04Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC)falsePGI+TGljZW7Dp2EgZGUgRGlzdHJpYnVpw6fDo28gTsOjbyBFeGNsdXNpdmE8L2I+DQoNClRvZG8gZGVwb3NpdGFudGUgZGUgbWF0ZXJpYWwgbm8gUGF0dcOhIGRldmUgY29uY2VkZXIgYW8gSW5zdGl0dXRvIEV2YW5kcm8gQ2hhZ2FzIHVtYSBMaWNlbsOnYSBkZSBEaXN0cmlidWnDp8OjbyBOw6NvIEV4Y2x1c2l2YSBwYXJhIHRvcm5hciBlIG1hbnRlciBhY2Vzc8OtdmVpcyBvcyBzZXVzIGRvY3VtZW50b3MgZW0gZm9ybWF0byBkaWdpdGFsLiANCg0KQ29tIGEgY29uY2Vzc8OjbyBkZXNzYSBsaWNlbsOnYSBuw6NvIGV4Y2x1c2l2YSwgbyBkZXBvc2l0YW50ZSBjb250aW51YSBhIHJldGVyIHRvZG9zIG9zIGRpcmVpdG9zIGRlIGF1dG9yLg0KDQpBbyBhc3NpbmFyIGUgZW50cmVnYXIgZXN0YSBsaWNlbsOnYSB2b2PDqiAoYXV0b3Igb3UgZGV0ZW50b3IgZG9zIGRpcmVpdG9zIGF1dG9yYWlzKQ0KDQphKSBEZWNsYXJhIHF1ZSBjb25oZWNlIGEgcG9sw610aWNhIGRlIGNvcHlyaWdodCBkYSBlZGl0b3JhIGRlIHNldSBkb2N1bWVudG8uDQoNCmIpIENvbmNlZGUgYW8gSW5zdGl0dXRvIEV2YW5kcm8gQ2hhZ2FzIG8gZGlyZWl0byBuw6NvIGV4Y2x1c2l2byBkZSBhcnF1aXZhciwgcmVwcm9kdXppciwgY29udmVydGVyIChjb21vIGRlZmluaWRvIGEgc2VndWlyKSwgY29tdW5pY2FyIGUvb3UgZGlzdHJpYnVpciBubyA8Yj5QYXR1w6E8L2I+LCBvIGRvY3VtZW50byBlbnRyZWd1ZSAoaW5jbHVpbmRvIG8gcmVzdW1vL2Fic3RyYWN0KSBlbSBmb3JtYXRvIGRpZ2l0YWwgb3UgcG9yIHF1YWxxdWVyIG91dHJvIG1laW8uDQoNCmMpIERlY2xhcmEgcXVlIGF1dG9yaXphIG8gSW5zdGl0dXRvIEV2YW5kcm8gQ2hhZ2FzIGEgYXJxdWl2YXIgbWFpcyBkZSB1bWEgY8OzcGlhIGRlc3NlIGRvY3VtZW50byBlIGNvbnZlcnTDqi1sbywgc2VtIGFsdGVyYXIgbyBzZXUgY29udGXDumRvLCBwYXJhIHF1YWxxdWVyIGZvcm1hdG8gZGUgZmljaGVpcm8sIG1laW8gb3Ugc3Vwb3J0ZSwgcGFyYSBlZmVpdG9zIGRlIHNlZ3VyYW7Dp2EsIHByZXNlcnZhw6fDo28gKGJhY2t1cCkgZSBhY2Vzc28uDQoNCmQpIERlY2xhcmEgcXVlIG8gZG9jdW1lbnRvIHN1Ym1ldGlkbyDDqSBvIHNldSB0cmFiYWxobyBvcmlnaW5hbCBlIHF1ZSBkZXTDqW0gbyBkaXJlaXRvIGRlIGNvbmNlZGVyIGEgdGVyY2Vpcm9zIG9zIGRpcmVpdG9zIGNvbnRpZG9zIG5lc3RhIGxpY2Vuw6dhLiBEZWNsYXJhIHRhbWLDqW0gcXVlIGEgZW50cmVnYSBkbyBkb2N1bWVudG8gbsOjbyBpbmZyaW5nZSBvcyBkaXJlaXRvcyBkZSBxdWFscXVlciBvdXRyYSBwZXNzb2Egb3UgZW50aWRhZGUuDQoNCmUpIERlY2xhcmEgcXVlLCBubyBjYXNvIGRvIGRvY3VtZW50byBzdWJtZXRpZG8gY29udGVyIG1hdGVyaWFsIGRvIHF1YWwgbsOjbyBkZXTDqW0gb3MgZGlyZWl0b3MgZGUgYXV0b3IsIG9idGV2ZSBhIGF1dG9yaXphw6fDo28gaXJyZXN0cml0YSBkbyByZXNwZWN0aXZvIGRldGVudG9yIGRlc3NlcyBkaXJlaXRvcywgcGFyYSBjZWRlciBhbyBJbnN0aXR1dG8gRXZhbmRybyBDaGFnYXMgb3MgZGlyZWl0b3MgcmVxdWVyaWRvcyBwb3IgZXN0YSBMaWNlbsOnYSBlIGF1dG9yaXphciBhIHV0aWxpesOhLWxvcyBsZWdhbG1lbnRlLiBEZWNsYXJhIHRhbWLDqW0gcXVlIGVzc2UgbWF0ZXJpYWwgY3Vqb3MgZGlyZWl0b3Mgc8OjbyBkZSB0ZXJjZWlyb3MgZXN0w6EgY2xhcmFtZW50ZSBpZGVudGlmaWNhZG8gZSByZWNvbmhlY2lkbyBubyB0ZXh0byBvdSBjb250ZcO6ZG8gZG8gZG9jdW1lbnRvIGVudHJlZ3VlLg0KDQpmKSBTRSBPIERPQ1VNRU5UTyBFTlRSRUdVRSBGT1IgQkFTRUFETyBFTSBUUkFCQUxITyBGSU5BTkNJQURPIE9VIEFQT0lBRE8gUE9SIE9VVFJBIElOU1RJVFVJw4fDg08gUVVFIE7Dg08gTyBJTlNUSVRVVE8gRVZBTkRSTyBDSEFHQVMsIERFQ0xBUkEgUVVFIENVTVBSSVUgUVVBSVNRVUVSIE9CUklHQcOHw5VFUyBFWElHSURBUyBQRUxPIFJFU1BFQ1RJVk8gQ09OVFJBVE8gT1UgQUNPUkRPLg0KDQpPIEluc3RpdHV0byBFdmFuZHJvIENoYWdhcyBpZGVudGlmaWNhcsOhIGNsYXJhbWVudGUgbyhzKSBub21lKHMpIGRvKHMpIGF1dG9yKGVzKSBkb3MgZGlyZWl0b3MgZG8gZG9jdW1lbnRvIGVudHJlZ3VlIGUgbsOjbyBmYXLDoSBxdWFscXVlciBhbHRlcmHDp8OjbyBhbMOpbSBkbyBwcmV2aXN0byBuYSBhbMOtbmVhIGIpLg==
dc.title.pt_BR.fl_str_mv Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil
title Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil
spellingShingle Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil
Justino, Maria Cleonice Aguiar
Gastroenterite / virologia
Rotavirus / isolamento & purificação
Vacinas contra Rotavirus
Hospitalização
title_short Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil
title_full Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil
title_fullStr Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil
title_full_unstemmed Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil
title_sort Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil
author Justino, Maria Cleonice Aguiar
author_facet Justino, Maria Cleonice Aguiar
Linhares, Alexandre da Costa
Lanzieri, Tatiana. M
Miranda, Ylle
Mascarenhas, Joana D'Arc Pereira
Abreu, Erika
Guerra, Sylvia de Fátima dos Santos
Oliveira, Alessilva S. L
Silva, Veronice B. da
Sanchez, Nervo
Meyer, Nadia
Shafi, Fakrudeen
Ortega-Barria, Eduardo
Soriano-Gabarró, Montse
Colindres, Romulo E
author_role author
author2 Linhares, Alexandre da Costa
Lanzieri, Tatiana. M
Miranda, Ylle
Mascarenhas, Joana D'Arc Pereira
Abreu, Erika
Guerra, Sylvia de Fátima dos Santos
Oliveira, Alessilva S. L
Silva, Veronice B. da
Sanchez, Nervo
Meyer, Nadia
Shafi, Fakrudeen
Ortega-Barria, Eduardo
Soriano-Gabarró, Montse
Colindres, Romulo E
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Justino, Maria Cleonice Aguiar
Linhares, Alexandre da Costa
Lanzieri, Tatiana. M
Miranda, Ylle
Mascarenhas, Joana D'Arc Pereira
Abreu, Erika
Guerra, Sylvia de Fátima dos Santos
Oliveira, Alessilva S. L
Silva, Veronice B. da
Sanchez, Nervo
Meyer, Nadia
Shafi, Fakrudeen
Ortega-Barria, Eduardo
Soriano-Gabarró, Montse
Colindres, Romulo E
dc.subject.decsPrimary.pt_BR.fl_str_mv Gastroenterite / virologia
Rotavirus / isolamento & purificação
Vacinas contra Rotavirus
Hospitalização
topic Gastroenterite / virologia
Rotavirus / isolamento & purificação
Vacinas contra Rotavirus
Hospitalização
description Background: Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. Methods: Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (≥12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (±8 and ±6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 - odds ratio X 100%). Results: Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1–86.0) using neighborhood controls and 40.0% (95% CI: 14.2–58.1) using hospital controls. VE in children 3 to 11 months and ≥12 months of age was 95.7% (95% CI: 67.8–99.4) and 65.1% (95% CI: 37.2–80.6) using neighborhood controls, and 55.6% (95% CI: 12.3–77.5) and 32.1% (95% CI: 3.7–55.5) using hospital controls. G2P[4] accounted for 82.0% of RVGE hospitalizations. G2P[4]-specific VE was 75.4% (95% CI: 56.7–86.0) using neighborhood controls and 38.9% (95% CI: 11.1– 58.0) using hospital controls. Conclusions: Although fully heterotypic G2P[4] was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 month months. However, protection in children ≥12 months of age, important for optimal public health impact, was significantly sustained based on estimates obtained using neighborhood controls.
publishDate 2011
dc.date.issued.fl_str_mv 2011
dc.date.accessioned.fl_str_mv 2016-01-26T11:39:50Z
dc.date.available.fl_str_mv 2016-01-26T11:39:50Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv JUSTINO, Maria Cleonice Aguiar et al. Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil. The Pediatric Infectious Disease Journal, v. 30, n. 5, p. 396-401, May 2011. DOI: https://doi.org/10.1097/INF.0b013e3182055cc2.
dc.identifier.uri.fl_str_mv https://patua.iec.gov.br/handle/iec/946
dc.identifier.issn.-.fl_str_mv 1871-0336
dc.identifier.doi.pt_BR.fl_str_mv 10.1097/INF.0b013e3182055cc2
identifier_str_mv JUSTINO, Maria Cleonice Aguiar et al. Effectiveness of the monovalent G1P [8] human rotavirus vaccine against hospitalization for severe G2P [4] rotavirus gastroenteritis in Belém, Brazil. The Pediatric Infectious Disease Journal, v. 30, n. 5, p. 396-401, May 2011. DOI: https://doi.org/10.1097/INF.0b013e3182055cc2.
1871-0336
10.1097/INF.0b013e3182055cc2
url https://patua.iec.gov.br/handle/iec/946
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/embargoedAccess
eu_rights_str_mv embargoedAccess
dc.format.none.fl_str_mv application/pdf
dc.coverage.temporalragefrom.-.fl_str_mv 2008
dc.coverage.temporalrageupto.-.fl_str_mv 2009
dc.publisher.none.fl_str_mv Lippincott, Williams & Wilkins
publisher.none.fl_str_mv Lippincott, Williams & Wilkins
dc.source.none.fl_str_mv reponame:Repositório Digital do Instituto Evandro Chagas (Patuá)
instname:Instituto Evandro Chagas (IEC)
instacron:IEC
instname_str Instituto Evandro Chagas (IEC)
instacron_str IEC
institution IEC
reponame_str Repositório Digital do Instituto Evandro Chagas (Patuá)
collection Repositório Digital do Instituto Evandro Chagas (Patuá)
bitstream.url.fl_str_mv https://patua.iec.gov.br/bitstreams/f67cca24-1d20-462c-9751-5f7b70e1e4cb/download
https://patua.iec.gov.br/bitstreams/0dcb8f4b-7333-47a4-9ca1-2e75bd1902b7/download
https://patua.iec.gov.br/bitstreams/98ac4a4d-20c7-4832-9498-6325a362efa9/download
https://patua.iec.gov.br/bitstreams/b3b14f19-ba3c-41f1-a0a8-ef28fd417ccd/download
https://patua.iec.gov.br/bitstreams/f72dc534-f82d-4f1b-a92b-a4e67d107297/download
https://patua.iec.gov.br/bitstreams/3a566108-0153-4295-b811-97d15d644748/download
https://patua.iec.gov.br/bitstreams/cd7006d8-5f36-4a95-9515-b88351b638a6/download
https://patua.iec.gov.br/bitstreams/bd078aab-ce17-4f7a-ae40-a3acc2ccbe79/download
https://patua.iec.gov.br/bitstreams/13470106-fb99-4821-acab-52cc99ecc50a/download
bitstream.checksum.fl_str_mv b4a728b35026c7be44f04c20fd8e113b
b4a728b35026c7be44f04c20fd8e113b
b4a728b35026c7be44f04c20fd8e113b
e1c06d85ae7b8b032bef47e42e4c08f9
45ce6e12ef4e729cfe9475020205fe2f
5b11fe0a61e28487f10cb9b29605b388
71859d578212107f7f8c49a4ce09d9ee
c9a9c128e29cac82a5d7fdf3f4e6da73
11832eea31b16df8613079d742d61793
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Digital do Instituto Evandro Chagas (Patuá) - Instituto Evandro Chagas (IEC)
repository.mail.fl_str_mv clariceneta@iec.gov.br || Biblioteca@iec.gov.br
_version_ 1809190040232787968